Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Tenet Healthcare shrugs off ACA headwinds with sweeping Q2 outperformance, boosts 2026 guidance
Overperformances across each side of Tenet Healthcare’s business have allowed the company to escape Affordable Care Act health insurance exchange-related hits that buried its for-profit peers.  | Bucking a trend set by its for-profit peers, the company outpaced the margin hit of substantial uninsured volume growth and boosted its 2026 guidance.
TL;DRAI
Tenet beat Q2 estimates (+$180M revenue, $5.62B total, $1.3B EBITDA), raising 2026 guidance despite 17% ACA exchange decline. Automation and AI-driven efficiency, combined with $300M+ ASC M&A, offset payer mix headwinds—healthcare's tech-driven margin defense strategy.
849 words~4 min read
